CN104105692B - 作为结核分枝杆菌靶向药物的苯并三嗪氧化物 - Google Patents

作为结核分枝杆菌靶向药物的苯并三嗪氧化物 Download PDF

Info

Publication number
CN104105692B
CN104105692B CN201280069153.0A CN201280069153A CN104105692B CN 104105692 B CN104105692 B CN 104105692B CN 201280069153 A CN201280069153 A CN 201280069153A CN 104105692 B CN104105692 B CN 104105692B
Authority
CN
China
Prior art keywords
compounds
alkyl
synthesized
esi
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280069153.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104105692A (zh
Inventor
P·马德瑞德
S·肖帕
K·莱恩
G·库佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Standford Institute For International Studies
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of CN104105692A publication Critical patent/CN104105692A/zh
Application granted granted Critical
Publication of CN104105692B publication Critical patent/CN104105692B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280069153.0A 2011-12-07 2012-12-07 作为结核分枝杆菌靶向药物的苯并三嗪氧化物 Expired - Fee Related CN104105692B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161567829P 2011-12-07 2011-12-07
US61/567,829 2011-12-07
PCT/US2012/068636 WO2013086467A1 (en) 2011-12-07 2012-12-07 Benzotriazine oxides as drugs targeting mycobacterium tuberculosis

Publications (2)

Publication Number Publication Date
CN104105692A CN104105692A (zh) 2014-10-15
CN104105692B true CN104105692B (zh) 2016-06-29

Family

ID=48574967

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280069153.0A Expired - Fee Related CN104105692B (zh) 2011-12-07 2012-12-07 作为结核分枝杆菌靶向药物的苯并三嗪氧化物

Country Status (5)

Country Link
US (2) US9663478B2 (enExample)
EP (1) EP2800744A4 (enExample)
JP (1) JP2015500295A (enExample)
CN (1) CN104105692B (enExample)
WO (1) WO2013086467A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500295A (ja) * 2011-12-07 2015-01-05 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類
CN110862357B (zh) * 2018-08-28 2021-06-08 浙江工业大学 一种苯并三嗪类化合物及其合成方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868371A (en) * 1972-02-01 1975-02-25 Bayer Ag 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxides and processes for their preparation
CN1068595C (zh) * 1995-12-04 2001-07-18 圣诺菲-合成实验室公司 制备3－氨基－1,2,4－苯并三嗪二氧化物的方法
WO2003042192A1 (en) * 2001-11-13 2003-05-22 Sanofi-Synthelabo Preparation of 3-amino-1,2,4-benzotriazine dioxide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
DE2255825C3 (de) * 1972-11-15 1978-03-30 Bayer Ag, 5090 Leverkusen Mikrobizide Mittel auf der Basis von S-N-Aminobenzo-l^-Triazin-di-N-oxiden (1,4)
US3991189A (en) * 1972-11-15 1976-11-09 Bayer Aktiengesellschaft Microbiocidal methods and compositions using substituted 1,2,4-triazine-1,4-di-N-oxide derivatives
IL44058A (en) * 1973-02-02 1978-10-31 Ciba Geigy Ag 3amino-1,2,4-benzotriazine 1,4-di-noxide derivatives, their preparation and compositions for the control of microorganisms containing them
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
WO1988002366A1 (en) * 1986-09-25 1988-04-07 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
EP0478545B1 (en) * 1989-09-18 1999-08-11 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
DE4244009A1 (de) * 1992-12-24 1994-06-30 Boehringer Mannheim Gmbh Verwendung von Benzotriazinen als PLA¶2¶-Inhibitoren, neue Benzotriazine, Verfahren zu ihrer Herstellung und Arzneimittel
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
GB0501999D0 (en) * 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CA2603088C (en) * 2005-03-31 2015-05-26 Auckland Uniservices Limited Tricyclic 1,2,4-triazine oxides and compositions therefrom for therapeutic use in cancer treatments
JP2015500295A (ja) * 2011-12-07 2015-01-05 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868371A (en) * 1972-02-01 1975-02-25 Bayer Ag 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxides and processes for their preparation
CN1068595C (zh) * 1995-12-04 2001-07-18 圣诺菲-合成实验室公司 制备3－氨基－1,2,4－苯并三嗪二氧化物的方法
WO2003042192A1 (en) * 2001-11-13 2003-05-22 Sanofi-Synthelabo Preparation of 3-amino-1,2,4-benzotriazine dioxide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tricyclic [1,2,4]Triazine 1,4-Dioxides As Hypoxia Selective Cytotoxins;Michael P. Hay，等;《J. Med. Chem.》;20081011;第51卷;第6853-6865页 *

Also Published As

Publication number Publication date
CN104105692A (zh) 2014-10-15
US20170217908A1 (en) 2017-08-03
EP2800744A1 (en) 2014-11-12
US9663478B2 (en) 2017-05-30
US20130150369A1 (en) 2013-06-13
EP2800744A4 (en) 2015-06-03
WO2013086467A1 (en) 2013-06-13
JP2015500295A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
CN107427521B (zh) 细胞周期蛋白依赖性激酶的抑制剂
CN109414596B (zh) Ash1l抑制剂和用其进行治疗的方法
CN111065639B (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN103121996B (zh) 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
JP6789239B2 (ja) Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
EP3461821B1 (en) Indole carboxamide compounds useful as kinase inhibitors
CA2950780C (en) Method for treating cancer using a combination of chk1 and atr inhibitors
KR102432420B1 (ko) (5,6-디하이드로)피리미도[4,5-e]인돌리진
EP2892880B1 (en) Indole carboxamide derivatives and uses thereof
JP2024514844A (ja) Ｍｙｔ１阻害剤を含む併用治療
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
EP3653620B1 (en) New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (hdac1-2)
JP2018522866A (ja) ４，６−ピリミジニレン誘導体およびこれらの使用
CN103003280A (zh) 作为cdk4/6抑制剂的氘化吡咯并嘧啶化合物
BR112016029612B1 (pt) compostos de di-hidroisoquinolinona substituídos
BRPI0711674A2 (pt) Método de inibição da proliferação indesejada, composto, composição e método de inibição
JP2020524148A (ja) 置換５−シアノインドール化合物及びその使用
JP2013532657A (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
JP2022537521A (ja) 小分子標的ブロモ／アセチルタンパク質およびその使用
CN117343048A (zh) 反式-1,4-环己二胺类化合物及其药用组合物和应用
CN104105692B (zh) 作为结核分枝杆菌靶向药物的苯并三嗪氧化物
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
CN103025722B (zh) 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性
CN104936964B (zh) 具有增强抗生素活性的活性的螺异噁唑啉化合物
US20250188092A1 (en) Rifamycin analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: American California

Patentee after: Standford Institute for International Studies

Address before: American California

Patentee before: Stanford Res Inst Int

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160629

Termination date: 20191207